Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Lucid Group Inc (LCID) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Lucid Group Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.65 (market cap $5.07B), while Lucid Group Inc trades at $6.49 (market cap $2.64B). The key difference: ACADIA Pharmaceuticals Inc. is the larger of the two by market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Lucid Group Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | LCID | |
|---|---|---|
Market Cap | $5.07B | $2.64B |
Sector | Health | Consumer Cyclical |
52-Week High | $29.41 | $24.77 |
52-Week Low | $20.06 | $4.62 |
Enterprise Value | $4.19B | $5.54B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.70, up 1.05% today, with a bullish technical trend and strong analyst support. The company reported robust Q2 2026 earnings, beating estimates with $0.18 EPS, and raised its 2026 revenue outlook. Revenue grew to $1.07 billion in 2025, with net income surging to $391 million, reflecting a 36.49% margin. Recent FDA Fast Track designation for remlifanserin in Alzheimer's disease psychosis adds to positive catalysts.
The outlook remains positive given earnings momentum and product sales growth, though high valuation multiples and recent negative cash flow pose risks. Analyst consensus targets $33.89, implying ~14% upside, with 70% recommending Buy. Key risks include clinical trial outcomes and competitive pressures in the biopharma sector.
Lucid (LCID) trades at $6.495, down 1.74% on the day, amid a bearish technical signal and weak fundamentals. The company reported a Q2 2026 EPS miss of -$3.30 versus -$2.41 expected, with revenue growth overshadowed by negative gross and net income margins. Recent news highlights an operational reset targeting $1.4 billion in cash savings and a delayed EV launch, reflecting ongoing challenges in the competitive EV market.
The outlook remains high-risk due to persistent losses and cash burn, though analyst consensus suggests modest upside to a $10.50 price target. Investment opportunities hinge on successful cost-cutting and robotaxi initiatives, while risks include execution missteps and intense competition. With 66.7% of analysts rating Hold, cautious optimism is tempered by financial instability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Lucid Group Inc
Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It is a vertically integrated company that designs, engineers, and builds electric vehicles, EV powertrains, and battery systems in-house using our own equipment and factory.
Read more on LCID →
